Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting

Filippi AR Alongi F Ciammella P De Bari B Franco P Livi L A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group). Rep Pract Oncol Radiother 2012;17 (5)259–261

Franco P Ciammella P Peruzzo Cornetto A The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. Med Oncol 2013;30 (4)729

De Bari B Chiesa S Filippi AR ; AIRO (Italian Association of Radiation Oncology) and the AIRO Palliative Care Group. The INTER-ROMA project—a survey among Italian radiation oncologists on their approach to the treatment of bone metastases. Tumori 2011;97 (2)177–184

Alongi F De Bari B Franco P ; AIRO Young and AIRO Prostate cancer Working Group. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med (Torino) 2013;118 (4)660–678

De Bari B Alongi F Franco P ; AIRO Young and AIRO Prostate cancer Working Group. The “PROCAINA (PROstate CAncer INdication Attitudes) Project” (Part II)—a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med (Torino) 2013;118 (7)1220–1239

Ciammella P De Bari B Fiorentino A ; AIRO Giovani (Italian Association of Radiation Oncology-Young Members Working Group). The “BUONGIORNO” project: burnout syndrome among young Italian radiation oncologists. Cancer Invest 2013;31 (8)522–528

De Bari B Franco P Ciammella P ; AIRO Giovani Italian Association of Radiation Oncology-Young Members Working Group. The PEDRO (Pocketable Electronic Devices in Radiation Oncology) project: how clinical practice is changing among young radiation oncologists. Tumori 2014;100 (6)e236–e242

De Bari B Franco P Niyazi M ; AIRO Giovani (Italian Association of Radiation Oncology-Young Members Working Group), of yDEGRO (Young German Society of Radiation Oncology), of SYROG (Spanish Young Radiation Oncology Group), of SEOR (Spanish Society of Radiation Oncology), of SPRO (Portuguese Society of Radiotherapy and Oncology-Young Members Working Group), SPRO Jovem), and of FYO (The Danish Association of Young Oncologists). The Pocketable Electronic Devices in radiation Oncology (PEDRO) Project: how the use of tools in medical decision making is changing? Technol Cancer Res Treat 2016;15 (2)365–376

De Bari B Fiorentino A Greto D Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori 2013;99 (6)637–649

Franco P De Bari B Ciammella P The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highligh ts from the 7^th Meeting of AIRO – Young Members Working Group (AIRO Giovani). Tumori 2014;100214e–229e

Ramnath N Dilling TJ Harris LJ Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3^rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143 5 Supple314S–e340S

Eberhardt WE De Ruysscher D Weder W ; Panel Members. 2^nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015;26 (8)1573–1588

De Leyn P Dooms C Kuzdzal J Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines. Transl Lung Cancer Res 2014;3 (4)225–233

Arriagada R Auperin A Burdett S ; NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375 (9722)1267–1277

PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352 (9124)257–263

Robinson CG Patel AP Bradley JD Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol 2015;33 (8)870–876

Hancock JG Rosen JE Antonicelli A Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery. Ann Thorac Surg 2015;99 (2)406–413

Wind J Smit EJ Senan S Eerenberg JP Residual disease at the bronchial stump after curative resection for lung cancer. Eur J Cardiothorac Surg 2007;32 (1)29–34

Riquet M Achour K Foucault C Le Pimpec Barthes F Dujon A Cazes A Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis. Ann Thorac Surg 2010;89 (3)870–875

Albain KS Swann RS Rusch VW Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374 (9687)379–386

Koshy M Goloubeva O Suntharalingam M Impact of neoadjuvant radiation on survival in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79 (5)1388–1394

Thomas M Rübe C Hoffknecht P ; German Lung Cancer Cooperative Group. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008;9 (7)636–648

Girard N Mornex F Douillard JY Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer 2010;69 (1)86–93

Katakami N Tada H Mitsudomi T A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 2012;118 (24)6126–6135

Sher DJ Fidler MJ Liptay MJ Koshy M Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer 2015;88 (3)267–274

Aupérin A Le Péchoux C Rolland E Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28 (13)2181–2190

Belderbos J Uitterhoeve L van Zandwijk N ; EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43 (1)114–121

Bezjak A Temin S Franklin G Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol 2015;33 (18)2100–2105

Aupérin A Le Péchoux C Pignon JP ; Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17 (3)473–483

Hanna N Neubauer M Yiannoutsos C ; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26 (35)5755–5760

Perez CA Stanley K Rubin P A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45 (11)2744–2753

Bradley JD Paulus R Komaki R Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16 (2)187–199

Bonner JA McGinnis WL Stella PJ The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 1998;82 (6)1037–1048

Cox JD Azarnia N Byhardt RW Shin KH Emami B Pajak TF A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8 (9)1543–1555

Baumann M Herrmann T Koch R ; CHARTWEL-Bronchus studygroup. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011;100 (1)76–85

Saunders M Dische S Barrett A Harvey A Griffiths G Parmar M (on behalf of the CHART steering committee). Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 1999;52 (2)137–148

Slawson RG Salazar OM Poussin-Rosillo H Amin PP Strohl R Sewchand W Once-a-week vs conventional daily radiation treatment for lung cancer: final report. Int J Radiat Oncol Biol Phys 1988;15 (1)61–68

Belderbos JS Heemsbergen WD De Jaeger K Baas P Lebesque JV Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66 (1)126–134

Chang JY Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced lung cancer. Semin Radiat Oncol 2015;25 (2)110–116

Govindan R Bogart J Stinchcombe T Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011;29 (23)3120–3125

van den Heuvel MM Uyterlinde W Vincent AD Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother Oncol 2014;110 (1)126–131

Wang J Xia TY Wang YJ Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81 (3)e59–e65

Okamoto I Takahashi T Okamoto H Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 2011;72 (2)199–204

Stinchcombe TE Morris DE Lee CB Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008;3 (3)250–257

Ready N Jänne PA Bogart J ; Cancer, Leukemia Group B, Chicago, IL. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010;5 (9)1382–1390

Kelly K Chansky K Gaspar LE Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26 (15)2450–2456

Komaki R Allen PK Wei X Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2015;92 (2)317–324

Herbst RS Prager D Hermann R ; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23 (25)5892–5899

Paez JG Jänne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304 (5676)1497–1500

Huber RM Reck M Thomas M Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J 2013;42 (4)1119–1133

Spigel DR Hainsworth JD Yardley DA Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28 (1)43–48

Butts C Socinski MA Mitchell PL START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;1559–68

Lynch TJ Bondarenko I Luft A Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012 302046–2054

Garon EB Rizvi NA Hui R Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;212018–2028

Borghaei H Paz-Ares L Horn L Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;3731627–1639

Brahmer J Reckamp KL Bass P Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373123–135

Sobin L Gospodarowicz M Wittekind C TNM Classification of Malignant Tumors, 7^th ed. Wiley-Blackwell, Oxford 2009

Crew KD Neugut AI Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31450–464

Leers JM Demeester SR Chan N Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 2009;138594–602

Rice TW Rusch VW Ishwaran H Blackstone EH Worldwide Esophageal Cancer C. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 116 3763–3773

Cellini F Morganti AG Matteo Di FM Mattiucci GC Valentini V Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiat Oncol 2014;945

NCCN Guidelines - Esophageal and Esophagogastric Cancers (excluding proximal 5 cm stomach). NCCN Clinical Practice Guideline in Oncology - Available at: http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf, (Version 2.2013). Accessed November 16, 2015.

Burmeister BH Role of radiotherapy in the pre-operative management of carcinoma of the esophagus. World J Gastrointest Oncol 2015;71–5

Walsh TN Noonan N Hollywood D Kelly A Keeling N Hennessy TP A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335462–467

Urba SG Orringer MB Turrisi A Iannettoni M Forastiere A Strawderman M Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19305–313

Burmeister BH Smithers BM Gebski V Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6659–668

Tepper J Krasna MJ Niedzwiecki D Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;261086–1092

Van Hagen P Hulshof MC Van Lanschot JJ Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;3662074–2084

Shapiro J van Lanschot JJ Hulshof MC Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomized controlled trial. Lancet Oncol 2015;161090–1098

Arnott SJ Duncan W Gignoux M Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998;41579–583

Greer SE Goodney PP Sutton JE Birkmeyer JD Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005;137172–177

Urschel JD Vasan H A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185538–543

Fiorica F Di Bona D Schepis F Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53925–930

Jin HL Zhu H Ling TS Zhang HJ Shi RH Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 2009;155983–5991

Sjoquist KM Burmeister BH Smithers BM Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12681–692

Wang DB Zhang X Han HL Xu YJ Sun DQ Shi ZL Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci 2012;573226–3233

Deng J Wang C Xiang M Liu F Liu Y Zhao K Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. Diagnostic pathology 2014;9151

Burmeister BH Thomas JM Burmeister EA Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011;47354–360

Stahl M Walz MK Stuschke M Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27851–856

Ronellenfitsch U Schwarzbach M Hofheinz R Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013;493149–3158

Cooper JS Guo MD Herskovic A Chemoradiotherapy of locally advanced esophageal cancer. JAMA 1999;2811623–1627

Crehange G Maingon P Peignaux K Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologies Digestive 9102. J Clin Oncol 2007;254895–4901

Minsky BD Pajak TF Ginsberg RJ INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined modality therapy for esophageal cancer: high-dose versus standard dose radiation therapy. J Clin Oncol 2002;201167–1174

Gaspar LE Winter K Kocha WI A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 2000;88988–95

Honing J Smit JK Muijs CT A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25638–643

Conroy T Galais MP Raoul JL Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15305–14

Ajani JA Winter K Komaki R Phase II randomized trial of two non-operative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;264551–4556

American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. J Clin Oncol 2006;243693–3704

Russi EG Sanguineti G Chiesa F Is there a role for postoperative radiotherapy following open partial laryngectomy when prognostic factors on the pathological specimen are unfavourable?A survey of head and neck surgical/radiation oncologists. Acta Otorhinolaryngol Ital 2013;33.311–319

Remacle M Hantzakos A Eckel H Endoscopic supraglottic laryngectomy: a proposal for a classification by the working committee on nomenclature, European Laryngological Society. Eur Arch Otorhinolaryngol 2009;266993–998

Remacle M Eckel HE Antonelli A Endoscopic cordectomy. A proposal for a classifcation by the Working Committee, European Laryngological Society. Eur Arch Otorhinolaryngol 2000;257227–231

Mendenhall WM Werning JW Hinerman RW Management of T1-T2 glottic carcinomas. Cancer 2004;1001786–1792

Potenza I Franco P Moretto F Exclusive radiotherapy for early-stage glottic cancer: a single-institution retrospective analysis with a focus on voice quality. Anticancer Res 2015;354155–4160

Russi EG Corvo’ R Merlotti A Swallowing dysfunction in head and neck cancer patents treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treat Rev 2012;381033–1049

Sanchez-Cuadrado I Castro A Bernaldez R Del Palacio A Gavilan J Oncologic outcomes after supracricoid partial laryngectomy. Otolaryngol Head Neck Surg 2011;144910–914

Denaro N Russi EG Lefebvre JL Merlano MC A systematic review of current and emerging approaches in the field of larynx preservation. Radiother Oncol 2014;11016–24

Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study. N Engl J Med 1991;3241685–1690

Lefebvre JL Andry G Chevalier D Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012;232708–2714

Forastiere AA Zhang Q Weber RS Long-term results of the RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2012;31845–852

Lefebvre JL Rolland F Tesselaar M Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Nat Cancer Inst 2009;101142–152

Pointreau Y Garaud P Chapet S Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101498–506

Posner MR Hershock DM Blajman CR Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;3571705–1715

Lefebvre JL Pointreau Y Rolland F Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013;31853–859

Numico G Franco P Cristofano A Is the combination of cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol 2013;85112–120

Franco P Potenza I Schena M Induction chemotherapy and sequential concomitant chemo-radiation in locally advanced head and neck cancers: how induction phase intensity and treatment breaks may impact on clinical outcomes. Anticancer Res 2015;356247–6254

Merlotti A Alterio D Vigna-Taglianti R Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology – head and neck working group. Radiat Oncol 2014;9264

Gebski V Burmeister B Smithers BM Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007226–234